1 / 3

14 November 2003 Washington, DC

PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUM Privacy Regulation of the Pharmaceutical Sector. 14 November 2003 Washington, DC Joan Antokol , Chief Privacy Officer Oliver Johnson, II , Chief Privacy Officer Novartis Pharmaceuticals Corporation Merck & Co., Inc.

lamis
Download Presentation

14 November 2003 Washington, DC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS AND BEST PRACTICES FORUMPrivacy Regulation of the Pharmaceutical Sector 14 November 2003 Washington, DC Joan Antokol, Chief Privacy Officer Oliver Johnson, II, Chief Privacy Officer Novartis Pharmaceuticals Corporation Merck & Co., Inc. John Clay, Senior Advisor, E-Business Jonathan Smollen, Chief Privacy Officer North American Commercial Operations Wyeth Pharmaceuticals Aventis Pharmaceuticals MODERATOR: Stanley Crosley, Chief Privacy Officer Eli Lilly and Company

  2. GLOBAL PRIVACY CONSIDERATIONS FOR PHARMACEUTICALCOMPANIES Sales Research (e.g, relationship with physicians, Patient Assistance Programs, prescriber data, preceptorships) (e.g., pharmacovigilance, subject recruitment, subject enrollment) Pharmaceutical Company Marketing Human Resources (customer relations management, e.g, call centers, web sites, coupons, business reply cards) (e.g, benefit plans, corporate health (on-site clinics), employee data) Other (e.g., stockholder services, investor relations)

  3. Overview I. Introductions II. Overview of Panel Discussion III. Panel Discussion • Business Case for Privacy Compliance • Practical Compliance Considerations IV. Questions & Answers

More Related